188 related articles for article (PubMed ID: 22199315)
41. Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma.
Ho AL; Koch MJ; Tanaka S; Eichler AF; Batchelor TT; Tanboon J; Louis DN; Cahill DP; Chi AS; Curry WT
J Clin Neurosci; 2016 Sep; 31():99-105. PubMed ID: 27279154
[TBL] [Abstract][Full Text] [Related]
42. IDH1R¹³²H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a.
Nie QM; Lin YY; Yang X; Shen L; Guo LM; Que SL; Li XX; Ge JW; Wang GS; Xiong WH; Guo P; Qiu YM
Mol Med Rep; 2015 Nov; 12(5):6695-701. PubMed ID: 26324126
[TBL] [Abstract][Full Text] [Related]
43. Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment.
Trautwein C; Zizmare L; Mäurer I; Bender B; Bayer B; Ernemann U; Tatagiba M; Grau SJ; Pichler BJ; Skardelly M; Tabatabai G
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34941573
[TBL] [Abstract][Full Text] [Related]
44. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
Khurshed M; Molenaar RJ; Lenting K; Leenders WP; van Noorden CJF
Oncotarget; 2017 Jul; 8(30):49165-49177. PubMed ID: 28467784
[TBL] [Abstract][Full Text] [Related]
45. An IDH1-mutated primary gliosarcoma: case report.
Hsieh JK; Hong CS; Manjila S; Cohen ML; Lo S; Rogers L; Sloan AE
J Neurosurg; 2017 Feb; 126(2):476-480. PubMed ID: 27153165
[TBL] [Abstract][Full Text] [Related]
46. Development of Autophagy Signature-Based Prognostic Nomogram for Refined Glioma Survival Prognostication.
Fan Y; Peng X; Li B; Zhao G
Biomed Res Int; 2020; 2020():1872962. PubMed ID: 32964017
[TBL] [Abstract][Full Text] [Related]
47. A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.
Kopinja J; Sevilla RS; Levitan D; Dai D; Vanko A; Spooner E; Ware C; Forget R; Hu K; Kral A; Spacciapoli P; Kennan R; Jayaraman L; Pucci V; Perera S; Zhang W; Fischer C; Lam MH
Sci Rep; 2017 Oct; 7(1):13853. PubMed ID: 29062039
[TBL] [Abstract][Full Text] [Related]
48. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.
Dimitrov L; Hong CS; Yang C; Zhuang Z; Heiss JD
Int J Med Sci; 2015; 12(3):201-13. PubMed ID: 25678837
[TBL] [Abstract][Full Text] [Related]
49. Transcriptomic Landscape of Lower Grade Glioma Based on Age-Related Non-Silent Somatic Mutations.
Park Y; Park J; Ahn JW; Sim JM; Kang SJ; Kim S; Hwang SJ; Han SH; Sung KS; Lim J
Curr Oncol; 2021 Jun; 28(3):2281-2295. PubMed ID: 34205437
[TBL] [Abstract][Full Text] [Related]
50. Transformation Foci in IDH1-mutated Gliomas Show STAT3 Phosphorylation and Downregulate the Metabolic Enzyme ETNPPL, a Negative Regulator of Glioma Growth.
Leventoux N; Augustus M; Azar S; Riquier S; Villemin JP; Guelfi S; Falha L; Bauchet L; Gozé C; Ritchie W; Commes T; Duffau H; Rigau V; Hugnot JP
Sci Rep; 2020 Mar; 10(1):5504. PubMed ID: 32218467
[TBL] [Abstract][Full Text] [Related]
51. [Monoclonal antibodies in high-grade gliomas].
Chekhonin IV; Leopold AV; Gurina OI; Semenova AV
Vestn Ross Akad Med Nauk; 2014; (9-10):131-9. PubMed ID: 25816654
[TBL] [Abstract][Full Text] [Related]
52. Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells.
Mesti T; Bouchemal N; Banissi C; Triba MN; Marbeuf-Gueye C; Cemazar M; Moyec LL; Carpentier AF; Savarin P; Ocvirk J
Radiol Oncol; 2018 Nov; 52(4):392-398. PubMed ID: 30511933
[TBL] [Abstract][Full Text] [Related]
53. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.
Neyns B; Sadones J; Joosens E; Bouttens F; Verbeke L; Baurain JF; D'Hondt L; Strauven T; Chaskis C; In't Veld P; Michotte A; De Greve J
Ann Oncol; 2009 Sep; 20(9):1596-1603. PubMed ID: 19491283
[TBL] [Abstract][Full Text] [Related]
54. Metabolic alterations due to IDH1 mutation in glioma: opening for therapeutic opportunities?
Mustafa DA; Swagemakers SM; Buise L; van der Spek PJ; Kros JM
Acta Neuropathol Commun; 2014 Jan; 2():6. PubMed ID: 24405933
[No Abstract] [Full Text] [Related]
55. Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples.
Feng E; Liang T; Wang X; Du J; Tang K; Wang X; Wang F; You G
J Neuroinflammation; 2019 Feb; 16(1):33. PubMed ID: 30755240
[TBL] [Abstract][Full Text] [Related]
56. Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions.
Piaskowski S; Bienkowski M; Stoczynska-Fidelus E; Stawski R; Sieruta M; Szybka M; Papierz W; Wolanczyk M; Jaskolski DJ; Liberski PP; Rieske P
Br J Cancer; 2011 Mar; 104(6):968-70. PubMed ID: 21326241
[TBL] [Abstract][Full Text] [Related]
57. An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation.
Shi J; Zuo H; Ni L; Xia L; Zhao L; Gong M; Nie D; Gong P; Cui D; Shi W; Chen J
Neurol Sci; 2014 Jun; 35(6):839-45. PubMed ID: 24362902
[TBL] [Abstract][Full Text] [Related]
58. Exploring the regulatory role of isocitrate dehydrogenase mutant protein on glioma stem cell proliferation.
Lu HC; Ma J; Zhuang Z; Qiu F; Cheng HL; Shi JX
Eur Rev Med Pharmacol Sci; 2016 Aug; 20(16):3378-84. PubMed ID: 27608896
[TBL] [Abstract][Full Text] [Related]
59. Overexpression of MCM6 predicts poor survival in patients with glioma.
Cai HQ; Cheng ZJ; Zhang HP; Wang PF; Zhang Y; Hao JJ; Wang MR; Wan JH
Hum Pathol; 2018 Aug; 78():182-187. PubMed ID: 29753008
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapy for high-grade glioma.
Dixit S
Future Oncol; 2014 May; 10(6):911-5. PubMed ID: 24941977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
